# SEG Drug HTML Source Review

**Review mode:** `CONTROLLED READ-ONLY SOURCE REVIEW`  
**Final gate:** `BLOCKED_PENDING_EXTERNAL_EVIDENCE_AND_MEDICAL_REVIEW`  
**Source artifact:** `/home/ubuntu/upload/deepseek_html_20260615_a3266b.html`  
**Authority:** YaAllah SEG source/governance rules remain controlling; this HTML is an intake artifact only.

## 1. Evidence identity

| Field | Observed value |
|---|---|
| File type | UTF-8 HTML (`text/html; charset=utf-8`) |
| Size | 25,918 bytes |
| Lines | 394 |
| SHA-256 | `5367711d08df2393cf852815b1b9d0ad4dac8240ac061cd88c71a53884e938ac` |
| Language/format signal | Arabic document with English clinical labels and JavaScript data arrays |
| Title signal | `الملخص الشامل لروزن وتينتينالي – الأدوية، الجرعات، الموانع` |
| Provenance supplied in artifact | No source ID, edition, publisher, owner, license, rights statement, locator contract, or audit record observed |
| Medical review state | Not supplied; therefore treated as `PENDING_CLINICAL_REVIEW` |
| Execution/import state | No execution, parsing into production records, import, activation, or learner exposure performed |

The title contains reference signals to Rosen and Tintinalli, but those signals do **not** prove an official source edition, publisher authorization, ownership, or display rights. The artifact is a derived HTML document containing embedded JavaScript data, not a governed SEG source record.

## 2. Structural inspection and counts

| Structure | Count | Evidence boundary |
|---|---:|---|
| `summaryData` top-level sections | 19 | 2 resuscitation/ventilation sections plus sections `sec1`–`sec17` |
| `quick` clinical summary entries | 21 | One compact symptoms/diagnosis/treatment object for each observed topic entry |
| `drugList` entities | 47 | Each object has `name`, `use`, `dose`, and `contraindications` fields |
| `trapsList` entries | 20 | Arabic exam-trap strings embedded in JavaScript |
| Rendered medication table | 1 | Generated client-side from `drugList` |
| Explicit interaction field/table | 0 | No normalized interaction schema or pairwise interaction table observed |
| Explicit source/version/SHA field | 0 | No governance envelope observed in the artifact |
| Explicit rights/medical-review/audit field | 0 | No governance state fields observed in the artifact |

The header advertises `40+` drugs and `120+` exam traps, while the inspectable arrays contain **47 drug entities** and **20 trap entries**. The `120+` claim is not supported by the observed `trapsList` and must not be used as a validated inventory count.

## 3. Observed clinical domains

The 19 sections cover resuscitation, ventilation, shock, cardiovascular disease, respiratory disease, gastrointestinal bleeding, sepsis, toxicology, renal colic, anticoagulation reversal, endocrine emergencies, stroke, compartment syndrome, pediatrics, ectopic pregnancy, ophthalmology, necrotizing infection, hypothermic arrest, and EMTALA. This is an inventory observation only. It is **not** a clinical correctness assessment and does not authorize educational use.

## 4. Medication entity classification

The following grouping is structural classification based on the `use` field in the artifact. It does not confirm indication, dose, contraindication, or clinical currency.

| Structural group | Observed entities |
|---|---|
| Resuscitation, airway, sedation, seizure | Propofol; Rocuronium; Succinylcholine; Lorazepam; Atropine |
| Cardiac rhythm and rate control | Adenosine; Amiodarone; Digoxin; Diltiazem; Esmolol; Procainamide; Propranolol |
| Shock, blood pressure, ischemia, thrombolysis | Aspirin; Dobutamine; Lactated Ringer's; Nicardipine; Nitroglycerin; Norepinephrine; Tenecteplase |
| Antimicrobial therapy | Ceftriaxone; Clindamycin; Moxifloxacin; Vancomycin |
| Toxicology and reversal | Digoxin-specific antibody fragments; Fomepizole; Glucagon; Idarucizumab; Methylene blue; N-acetylcysteine; Pralidoxime; Protamine sulfate; Prothrombin complex concentrate; Pyridoxine; Sodium bicarbonate |
| Analgesia, antiemetic, gastrointestinal and symptomatic care | Diclofenac; Ibuprofen; Metoclopramide; Ondansetron |
| Endocrine, obstetric, inflammatory and hemostatic use | Dexamethasone; Hydrocortisone; Magnesium sulfate; Methotrexate; Tranexamic acid; Ulipristal acetate |
| Other/volume or renal support | Furosemide |

The artifact includes 47 distinct `drugList` object entries by structural count. The grouping above is not a canonical SEG taxonomy and must not be copied into a production taxonomy without a governed mapping decision.

## 5. Interaction and precaution signals

No formal interaction model is present. The following are **observed text signals** in the `contraindications` or precaution strings and are recorded for later clinical review only:

| Observed signal | Entities carrying the signal | Classification |
|---|---|---|
| WPW with atrial fibrillation | Adenosine; Digoxin; Diltiazem; Procainamide is listed for this use | Cross-condition contraindication/indication signal; requires clinical verification |
| QT or torsade risk | Amiodarone; Haloperidol; Ondansetron; Moxifloxacin; Procainamide | Precaution/contraindication signal; not a normalized interaction record |
| MAOI or serotonergic-risk signal | Methylene blue | Drug–drug precaution signal; requires clinical verification |
| PDE5 inhibitor co-use | Nitroglycerin | Drug–drug precaution signal; requires clinical verification |
| Renal function/renal failure | Diclofenac; Furosemide; Ibuprofen; Vancomycin; Methotrexate and others | Organ-function precaution signal; not a complete interaction model |
| Bleeding/thrombosis state | Aspirin; PCC; Tenecteplase; Tranexamic acid; Protamine and others | Clinical-context precaution signal; requires source and medical review |
| Pregnancy/obstetric context | Ibuprofen; Methotrexate; Ulipristal; Dexamethasone and others | Population/context precaution signal; requires clinical review |

This table deliberately preserves the distinction between **observed wording** and a validated drug-interaction database. No interaction finding is approved, activated, or imported.

## 6. Comparison with SEG baseline

The SEG baseline requires every future content candidate to preserve at least: `Source`, `Version`, `SHA-256`, `Rights Status`, `Medical Review Status`, track/taxonomy context, and an append-only `Audit Trail`. The HTML provides a file-level SHA-256 after this review, but it does not contain a source/version/rights/clinical-review/audit envelope and does not provide reliable locators back to an authoritative source edition.

| Baseline requirement | Current HTML evidence | Readiness result |
|---|---|---|
| Source identity and lineage | Rosen/Tintinalli title signal only | `MISSING / EXTERNAL EVIDENCE REQUIRED` |
| Version/edition | Not observed | `MISSING` |
| File SHA-256 | Available from this intake fingerprint | `OBSERVED_FOR_ARTIFACT_ONLY` |
| Rights/display status | Not observed | `MISSING / BLOCKING` |
| Medical review status | Not observed | `PENDING_CLINICAL_REVIEW / BLOCKING` |
| Audit trail | Not observed | `MISSING / BLOCKING` |
| Professional track | Not explicit; possible emergency-medicine signal is not a governed track assignment | `UNRESOLVED` |
| Locator/reference contract | Embedded data only; no source locator contract | `MISSING / BLOCKING` |
| Drug entity normalization | Flat JavaScript objects | `REQUIRES_GOVERNED_ADAPTATION` |
| Interaction model | Textual contraindication strings only | `REQUIRES_CLINICAL_REVIEW; NOT A DATABASE` |
| Schema compatibility | Not a `SEG_CONTENT_RECORD_V1_1` envelope | `ADAPT_BEFORE_ANY_FUTURE_MAPPING` |

## 7. Governance decision

**Disposition:** `REVIEW_REQUIRED` for future source-governance intake; `REJECT` for direct import, production JSON generation, database seeding, activation, or learner exposure.

The HTML may be retained as a read-only evidence artifact. It may not be treated as an approved drug reference, a validated dose table, an interaction database, or a replacement for an authoritative source. No content rewriting or medical correction was performed.

## 8. Required evidence before any later phase

A later controlled phase would require an independently verifiable source identity and edition, rights/display evidence, precise locators, track decision, clinical reviewer assignment and decision record, duplicate/lineage decision, and an explicit mapping review against the canonical `SEG_CONTENT_RECORD_V1_1` contract. The existing SEG rule remains **Reuse → Organize → Create**; no source is deleted, replaced, merged, imported, activated, or exposed by this review.

## 9. Non-actions and validation

- The source HTML was not modified.
- The HTML was not executed in a browser or runtime as part of this review.
- No SQL, Prisma operation, seed, migration, Supabase change, content record, adapter, mapping, import, activation, or learner exposure was performed.
- The reported counts were obtained from the static HTML structure and JavaScript arrays only.

## References

[1]: `/home/ubuntu/upload/deepseek_html_20260615_a3266b.html` "Drug HTML intake artifact"
[2]: `/home/ubuntu/seg-internship-output/SEG_PHASE_7_8_11_UPDATED_SOURCE_REGISTRY.md` "SEG Phase 7.8.11 updated source registry and governance gates"
[3]: `/home/ubuntu/seg-manus-status/schemas/SEG_CONTENT_RECORD_V1_1/SEG_CONTENT_RECORD_V1_1.schema.json` "Canonical SEG_CONTENT_RECORD_V1_1 schema"
[4]: `/home/ubuntu/seg-internship-output/SEG_CONTENT_STORAGE_DESIGN.md` "SEG content storage and source-family boundary"
[5]: `/home/ubuntu/upload/pasted_content_23.txt` "Prior OSCE/source and database claims reviewed as external evidence"
